Safety and Efficacy of Feroxyl®, a Special Iron Bisglycinate Preparation in Improving Hemoglobin and Blood Biomarkers in Lebanese Patients with Iron Deficiency and Iron Deficiency Anemia: A Retrospective Chart Review
Patrick Choueiry, Pierre Haddad, Joe Baroudy, Rana Fassih, Salma Tradieh, Joseph Kareh, Wassim Jreij, Tanios Otayek, Imad Elias, Paul Makhlouf, Mariam Farhat, Jihad Ezzedine, Mohamad Hayek, Lina Jarrah, Rola Deeb and Iman Akoush
Anemia is a widespread public health issue, with iron deficiency anemia (IDA) responsible for 50% of
cases. This study evaluates the effectiveness of Feroxyl, a ferrous bisglycinate supplement enriched with
vitamins, in improving hemoglobin and other blood biomarkers among a cohort of Lebanese patients
with ID or IDA. A retrospective chart review of 593 patients showed significant improvements in
hemoglobin (1.81 g/dL increase) and biomarkers like MCV, MCH, as well as ferritin after three months
of supplementation. Vitamin D also significantly Increased. The supplement was well-tolerated, with
mild side effects, making Feroxyl a promising treatment for IDA, particularly in low-resource settings.
